HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)
- 147 Downloads
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third cause of cancer death globally with most deaths occurring within 1 year of diagnosis. HCC is the sixth most common malignancy worldwide [1, 2, 3]. Transplantation and resection remain the only potentially curative options . Locoregional therapies such as chemoembolization (TACE) and radiofrequency ablation have an established palliative role in select patients [5, 6, 7, 8, 9]. Targeted molecular therapies now have a recognized role, with sorafenib demonstrating improved survival in patients with advanced HCC [10, 11].
Selective internal radiation (SIRT) treatment with Y-90 Microsphere goals are to increase the time to progression, extend overall survival, potentially downsize or downstage tumors for liver resection, ablation or transplantation, and provide palliation of symptoms. Y-90 Microsphere is a high-energy beta-emitting isotope with no primary gamma emission. The maximum...
- 13.MDS Nordion. Package Insert for TheraSphereYttrium-90 glass microspheres. http://www.nordion.com/therasphere/physicians-packageinsert/package-insert-us.pdf
- 15.Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23. doi: 10.1016/j.ijrobp.2006.11.060.CrossRefPubMedGoogle Scholar
- 19.Soydal C, Alkan A, Ozkan E, Demirkazık A, Kucuk NO. Ga-68 PSMA accumulation in hepatocellular carcinoma. Clin Oncol. 2016;1:1091.Google Scholar